Article
BRAFV600E mutation status of involuting and stable nevi in dabrafenib therapy with or without trametinib.
JAMA dermatology - 1 Oct 2014
McClenahan Phil, Lin Lynlee L, Tan Jean-Marie, Flewell-Smith Ross, Schaider Helmut, Jagirdar Kasturee, Atkinson Victoria, Lambie Duncan, Prow Tarl W, Sturm Richard A, Soyer H Peter
Abstract excerpt
IMPORTANCE: Recent advances in targeting BRAFV600E mutations, which occur in roughly 50% of melanomas and 70% of benign nevi, have improved response rates and survival in patients with melanoma. With increased survival, the importance of other comorbidities increases and requires consideration in long-term management. This case report discusses dynamic dermoscopic nevus changes that occur during dabrafenib...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.